睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of YL202 in Selected Patients With Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 45 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 45

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心桂林医学院附属医院Affiliated Hospital of Guilin Medical University桂林医院页面
  3. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  4. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  5. 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
  6. 研究中心吉林大学白求恩第三医院(中日联谊医院)China-Japan Union Hospital, Jilin University长春医院页面
  7. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  8. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  9. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  10. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  11. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  12. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  13. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  14. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  15. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  16. 研究中心复旦大学附属华山医院Huashan Hospital上海医院页面
  17. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  18. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  19. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  20. 研究中心梅州市人民医院Meizhou People's Hospital梅州医院页面
  21. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  22. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  23. 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
  24. 研究中心重庆医科大学附属第二医院Second Affiliated Hospital of Chongqing Medical University重庆医院页面
  25. 研究中心苏州大学附属第二医院Second Affiliated Hospital of Soochow University苏州医院页面
  26. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
  27. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  28. 研究中心上海市第一人民医院Shanghai General Hospital上海医院页面
  29. 研究中心上海交通大学医学院附属第九人民医院Shanghai Ninth People's Hospital上海医院页面
  30. 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
  31. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  32. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  33. 研究中心中山大学附属第六医院Sixth Affiliated Hospital of Sun Yat-sen University广州医院页面
  34. 研究中心陆军军医大学第一附属医院(西南医院)Southwest Hospital, Army Medical University重庆医院页面
  35. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  36. 研究中心浙江省台州医院Taizhou Hospital台州医院页面
  37. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  38. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  39. 研究中心潍坊市人民医院Weifang People's Hospital潍坊医院页面
  40. 研究中心四川大学华西医院West China Hospital成都医院页面
  41. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  42. 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
  43. 研究中心徐州市中心医院Xuzhou Central Hospital徐州医院页面
  44. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  45. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06107686,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed at diagnosis of NSCLC/BC/HNSCC/other locally advanced or metastatic solid tumors including but not limited to colorectal cancer, HER2-positive gastric cancer, cervical cancer, ovarian cancer, etc..

    入选标准第 3 条

  3. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).

    排除标准第 1 条

    Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study.

    排除标准第 5 条

    Prior treatment with systemic steroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product.

    排除标准第 7 条

  4. With Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.

    入选标准第 6 条

  5. At least one extracranial measurable lesion according to RECIST 1.1.

    入选标准第 4 条

  6. With known human immunodeficiency virus (HIV) infection.

    排除标准第 17 条

    With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

    排除标准第 18 条

    With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product.

    排除标准第 19 条

  7. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. Male subjects must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product.

    入选标准第 8 条

    Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06107686,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects who are aware of relevant trial information before the start of the trial, and voluntarily sign and date on the informed consent form (ICF).
  2. Subjects aged from 18-75 (inclusive) years.
  3. Histologically or cytologically confirmed at diagnosis of NSCLC/BC/HNSCC/other locally advanced or metastatic solid tumors including but not limited to colorectal cancer, HER2-positive gastric cancer, cervical cancer, ovarian cancer, etc..
  4. At least one extracranial measurable lesion according to RECIST 1.1.
  5. Archived or fresh tumor tissue samples can be provided.
  6. With Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
  7. The function of organs and bone marrow meets the requirements within 7 days before the first dose.
  8. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. Male subjects must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product.
  9. With expected survival ≥ 3 months.
  10. Be capable of and willing to comply with the visits and procedures stipulated in the study protocol.

排除标准:Exclusion Criteria:

  1. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).
  2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
  3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study.
  4. The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product.
  5. Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study.
  6. Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation.
  7. Prior treatment with systemic steroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product.
  8. Patients who have received any live vaccine within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period.
  9. With meningeal metastasis or cancerous meningitis.
  10. With brain metastasis or spinal cord compression.
  11. Patients with uncontrolled or clinically significant cardiovascular diseases.
  12. Clinically significant complicated pulmonary disorders.
  13. Patients diagnosed with Gilbert syndrome.
  14. Those with uncontrolled effusion in the third space requiring repeated drainage.
  15. With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator.
  16. With serious infection before the first dose.
  17. With known human immunodeficiency virus (HIV) infection.
  18. With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  19. With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product.
  20. Unrelieved toxicity of previous anti-tumor therapy.
  21. With a history of severe hypersensitivity to inactive ingredients in the raw materials and drug product or other monoclonal antibodies.
  22. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose.
  23. With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.

引自 ClinicalTrials.gov, NCT06107686, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06107686,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06107686